Tetrabenazine-d6 – 1 mg

Brand:
Cayman
CAS:
1392826-25-3
Storage:
-20
UN-No:
Non-Hazardous - /

Tetrabenazine-d6 is intended for use as an internal standard for the quantification of tetrabenazine (Item No. 20380) by GC- or LC-MS. Tetrabenazine is an inhibitor of vesicular monoamine transporter 2 (VMAT2) that is selective over VMAT1 (Kis = 97 and >20,000 nM, respectively, in a serotonin uptake assay).{26973} It dose-dependently reduces levels of the monoamines norepinephrine (Item No. 16673), dopamine (Item No. 21992), and serotonin (5-HT; Item No. 14332) in rat brain and has been used to induce depressive-like behavior in animal models.{47227,47228} Tetrabenazine (5 mg/kg) improves performance in balance beam and rotarod tests and prevents decreases in the number of striatal medium spiny neurons (MSNs) in a YAC128 transgenic mouse model of Huntington’s disease.{47229} Formulations containing tetrabenazine have been used in the treatment of chorea associated with Huntington’s disease.  

 

Available on backorder

SKU: 26811 - 1 mg Category:

Description

An internal standard for the quantification of tetrabenazine by GC- or LC-MS


Formal name: rel-1,3R,4,6,7,11bR-hexahydro-9,10-di(methoxy-d3)-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-one

Synonyms:  TBZ-d6

Molecular weight: 323.5

CAS: 1392826-25-3

Purity: ≥99% deuterated forms (d1-d6)

Formulation: A crystalline solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Transporter & Exchanger Modulators||Research Area|Neuroscience|Behavioral Neuroscience|Depression||Research Area|Neuroscience|Neurodegenerative Disorders|Huntington’s Disease||Research Area|Neuroscience|Neuroprotection